Abstract
The four serotypes of dengue virus (DENV) are the leading cause of arboviral diseases in humans. Decades of efforts have made remarkable progress in dengue vaccine development. Despite the first dengue vaccine (dengvaxia from Sanofi Pasteur), a live-attenuated tetravalent chimeric yellow fever-dengue vaccine, has been licensed by several countries since 2016, its overall moderate efficacy (56.5–60.8%) in the presence of neutralizing antibodies during the Phase 2b and 3 trials, lower efficacy among dengue naïve compared with dengue experienced individuals, and increased risk of hospitalization among young children during the follow-up highlight the need for a better understanding of humoral responses after natural DENV infection. Recent studies of more than 300 human monoclonal antibodies (mAbs) against DENV have led to the discovery of several novel epitopes on the envelope protein recognized by potent neutralizing mAbs. This information together with in-depth studies on polyclonal sera and B-cells following natural DENV infection has tremendous implications for better immunogen design for a safe and effective dengue vaccine. This review outlines the progress in our understanding of mouse mAbs, human mAbs, and polyclonal sera against DENV envelope and precursor membrane proteins, two surface proteins involved in vaccine development, following natural infection; analyses of these discoveries have provided valuable insight into new strategies involving molecular technology to induce more potent neutralizing antibodies and less enhancing antibodies for next-generation dengue vaccine development.
Introduction
The four serotypes of dengue virus (DENV) cause the most common and important arboviral diseases in humans (Guzman and Harris, ). Approximately 390 million DENV infections occur annually with 20–25% apparent infection, including dengue fever (DF), and a severe and potentially life-threatening disease, dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS) (World Health Organization, 2009; Bhatt et al., ; Guzman and Harris, ). Decades of efforts have made tremendous progress in dengue vaccine development; several candidate vaccines are currently in different phases of clinical trials (Murphy and Whitehead, 2011; Schwartz et al., 2015). Despite the Sanofi Pasteur's dengvaxia, a live-attenuated chimeric yellow fever-dengue tetravalent dengue vaccine (CYD-TDV), has been licensed as the first dengue vaccine by several countries since 2016, the moderate efficacy (56.5–60.8%) in the presence of neutralizing antibodies (Abs) during its Phase 2b and 3 trials, lower efficacy among dengue naïve compared with dengue experienced individuals (35.5–43.2 vs. 74.3–83.7%), and increased risk of hospitalization and severe dengue among young children during the follow-up in years 3–6 highlight the need for a better understanding of immunity, in particular humoral responses, after natural DENV infection (Sabchareon et al., 2012; Capeding et al., ; Guy et al., ; Hadinegoro et al., ; Thomas, 2015; Villar et al., 2015; Aguiar et al., ; Flasche et al., ; Halstead, ; Halstead and Russell, ; Wilder-Smith et al., 2016). Recent studies of more than 300 human monoclonal antibodies (mAbs) have led to the discovery of several potent neutralizing epitopes; these together with detailed analysis of polyclonal sera and B-cells after natural infection have provided valuable insights into dengue vaccine development. This review outlines the progress in our understanding of the epitopes and specificity of mouse mAbs, human mAbs and polyclonal sera against DENV surface proteins, the envelope (E) and precursor membrane (prM) proteins, following natural infection; and their implication for new strategies of dengue vaccine to induce more potent neutralizing Abs and less enhancing Abs.
Genome, virion structure, assembly, and maturation
The genome of DENV consists of a positive-sense, single-stranded RNA of 10.6 kb in length. Flanked by the 5′ and 3′ untranslated regions, the single open reading frame encodes a polyprotein precursor, which is cleaved by cellular and viral protease into three structural proteins, the capsid (C), prM, and E, and seven non-structural (NS) proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 (Murphy and Whitehead, 2011; Pierson and Diamond, 2013).
The E protein, ~55 kDa in size, contains two N-linked glycans and 12 strictly conserved cysteines forming 6 disulfide bridges (Pierson and Diamond, 2013). It contains 495 (DENV1, 2, 4) or 493 (DENV3) amino acids. As the major surface protein present on virions, E protein participates in virus entry and is the main target of neutralizing and enhancing Abs (Murphy and Whitehead, 2011; Pierson and Diamond, 2013). The ectodomain at the N-terminus contains three distinct domains. Domain I (DI) is located in the center, domain II (DII), an elongated domain containing the fusion loop at its tip, is involved in dimerization and membrane fusion, and domain III (DIII), an immunoglobulin-like domain, is involved in receptor binding and stabilization of trimers during fusion (Modis et al., 2004; Pierson and Diamond, 2013). At the C-terminus, there are two α-helices in the stem region and two transmembrane domains in the anchor region (Zhang W. et al., 2003; Pierson and Diamond, 2013).
The prM protein, ~19 kDa in size, contains one N-linked glycan and 6 highly conserved cysteines forming 3 disulfide bridges (Pierson and Diamond, 2013). The prM protein consists of 166 amino acids; during maturation of virions it is cleaved into the pr peptide (91 residues) and membrane (M) protein (75 residues), which includes an N-terminal loop, an α-helical domain, and two transmembrane domains (Pierson and Diamond, 2013; Zhang et al., 2013). After biosynthesis, prM protein forms a heterodimer with E protein to function as a chaperone for E protein and prevent premature fusion of E protein within acidic compartments along the secretory pathway (Mukhopadhyay et al., 2005; Pierson and Diamond, 2013).
DENV enters the cell through receptor mediated endocytosis. The low-pH environment in endosome results in conformational change of E protein and fusion between viral and endosomal membranes (Modis et al., 2004; Mukhopadhyay et al., 2005; Kielian and Rey, ; Pierson and Diamond, 2013). The assembly of DENV occurs in the membranes derived from rough ER, where the immature virions bud into the lumen of ER and transport through the secretary pathway (Mukhopadhyay et al., 2005; Pierson and Diamond, 2013). Within the low pH environment of trans-Golgi the prM protein on immature virions is cleaved by furin or furin-like protease into pr peptide and M protein; pr is released under neutral pH in the culture medium to form mature particles (Perera and Kuhn, 2008; Yu et al., 2008). However, the prM cleavage is inefficient, leading to a mixture of mature, immature and partially immature DENV particles in tissue culture (Cherrier et al., ; Junjhon et al., ). Cryo-EM studies have revealed structural details of mature and immature DENV particles as shown in Figure 1.
Figure 1
DENV proteins recognized by Abs after DENV infection
Following primary DENV infection, individuals develop an IgM response, followed by an IgG response. After secondary DENV infection, individuals develop a greater IgG response compared to IgM response (Innis, ; Vaughn et al., 1999). IgM response is relevant to dengue diagnosis, whereas IgG response is critical to pathogenesis, protection or enhancement, and vaccine development.
Different assays have been employed to study Abs response after DENV infection, including enzyme-linked immunosorbent assay (ELISA), Western blot (WB) and microsphere immunoassay to examine binding Abs, as well as neutralization and enhancing assays for functional Abs. Most binding assays, which use either DENV virions or recombinant E protein as antigen, provide little information on Abs targeting different DENV proteins, whereas WB analysis that employs antigens derived from DENV-infected cells can detect Abs responses to individual DENV proteins and their relative abundance. Early studies reported E, NS3, and NS5 proteins were recognized (Churdboonchart et al., ; Se-Thoe et al., 1999; Valdes et al., 2000). Later studies revealed that the strongest Abs response was anti-E Abs which recognize both the infecting DENV serotype and three other serotypes plus West Nile virus (WNV), a member of Japanese encephalitis virus (JEV) serocomplex, followed by anti-prM and anti-NS1 Abs after primary DENV infection (Figure 2A). Following secondary infection, strong cross-reactive anti-E Abs plus anti-prM and anti-NS1 Abs were found (Figure 2B) (Lai et al., ; Tsai et al., 2015). A similar trend was observed in vaccinees following primary and secondary immunization with monovalent live-attenuated DENV vaccines (Figures 2C,D). Together, these observations suggest that cross-reactive anti-E Abs are the major Abs, followed by anti-prM and NS1 Abs.
Figure 2
Different categories of anti-E mAbs: binding specificity and epitopes
In the genus Flavivirus of the family Flaviviridae, members belonging to different serocomplexes cause significant human diseases, including the four serotypes of DENV in the DENV serocomplex, WNV and JEV in the JEV serocomplex, tick-borne encephalitis virus (TBEV) in the TBEV serocomplex, YFV as a single member, and Zika virus (ZIKV) in its serocomplex (Pierson and Diamond, 2013). The amino acid sequence homology of E protein is about 39–49% between different serocomplexes, 63–78% between DENV serotypes, and up to 96–97% between genotypes within each DENV serotype (Stiasny et al., 2006). Based on the binding specificity, anti-E Abs that recognize members of two or more serocomplexes, members within the same serocomplex, or a single member are categorized as group-reactive, complex-reactive, and type-specific Abs, respectively (Calisher et al., ). Determining the binding specificity of anti-DENV Abs provides important information on the extent of cross-reactivity to different flaviviruses, but this requires the inclusion of 4 DENV serotypes and other flaviviruses as antigens in the binding assay. Most studies utilized antigens from 4 serotypes only and classified anti-DENV Abs as type-specific and cross-reactive Abs, which include both complex-reactive and group-reactive Abs.
DENV E protein contains both linear and discontinuous epitopes. Linear epitopes can be identified by peptide-scan ELISA; discontinuous epitopes can be identified by alanine-scanning or shortgun mutagenesis, yeast or phage-display library, neutralization escape mutant, and cryo-EM analysis of Fab and virions. Although a few linear epitopes on E protein have been reported based on peptide ELISA of dengue-immune sera (Aaskov et al., ; Megret et al., 1992; da Silva et al., ), the majority of anti-E Abs likely recognize discontinuous and conformational epitopes. The evidence came from studies of mouse anti-E mAbs and anti-E Abs in human sera, in which most lost binding in WB analysis under reducing condition and were thus sensitive to the conformation provided by disulfide bridges (Megret et al., 1992; Roehrig et al., 1998; Lai et al., ). Consistent with this, a mutational study revealed that the 6 disulfide bridges formed by 12 cysteines were critical for the epitope expression and conformation of DENV E protein (Roehrig et al., 2004).
Epitopes recognized by mouse anti-E mAbs
Studies of mouse mAbs against DENV have shown that different categories of anti-E mAbs have different epitopes and neutralizing potency. Group-reactive mAbs primarily recognize the highly conserved residues in the fusion loop of DII, whereas complex-reactive and type-specific mAbs recognize different but slightly overlapping residues in DIII (Crill and Chang, ; Gromowski and Barrett, ; Gromowski et al., ; Lin et al., ). The neutralizing potency of type-specific mAbs was generally higher than that of complex-reactive mAbs, which in turn was higher than that of group-reactive mAbs (Gromowski and Barrett, ; Sukupolvi-Petty et al., 2007; Gromowski et al., ). Several type-specific anti-DIII potent neutralizing mAbs (NT50 in the range of ng/ml) have been reported as potential therapeutic mAbs (Brien et al., ; Shrestha et al., 2010; Sukupolvi-Petty et al., 2010, 2013). It should be noted that these potent neutralizing mAbs were generated by an immunization protocol including two DENV infections in the IFN-α/β receptor-deficient (IFN-αβR−/−) strain in the C57BL/6 background followed by boost with recombinant DIII (rDIII), which was different from early protocols using DENV to immunize wild type (WT) BALB/c mice (Gromowski and Barrett, ; Sukupolvi-Petty et al., 2007; Lin et al., ). More than 200 mouse anti-E mAbs including several potent neutralizing mAbs are summarized in Table 1.
Table 1
| Immunogena | # of mAbs | Specificityb TS/CrR[CR+GR] | Bindingc DI/II DIII E | Epitopesd | Potent NT mAbs or remarkse | References | |
|---|---|---|---|---|---|---|---|
| DENV1 | 67 | 30 TS (45%) 30 CrR (45%) 7 ND | 5 5 4 | 25 25 3 | DIII: lr, str A and str G | 15 strong NT mAbs 14 anti-DIII | Shrestha et al., 2010 |
| DENV2 | 33 | 20 TS (61%) 11 CrR (33%) 2 ND | 8 6 2 | 11 1 5 | DIII: lr, CCL and str A, DI: lr, DII: lr, di and FL | 24 strong NT mAbs 11 anti-DIII, 13 anti-DI/DII | Sukupolvi-Petty et al., 2010 |
| DENV3 | 74 | 48 TS (65%) 24 CrR (32%) 2 ND | 13 15 2 | 25 10 4 5 | DIII: lr, str A and str G | 22 strong NT mAbs 19 anti-DIII | Brien et al., |
| DENV4 | 47 | 26 TS (55%) 17 CrR (36%) 4 ND | 6 9 2 | 13 7 5 3 2 | DIII: lr, CCL, str F and str G | 6 strong NT mAbs 5 anti-DIII | Sukupolvi-Petty et al., 2013 |
Summary of mouse anti-E mAbs reported in four large studies.
Immunization protocol: IFN-αβR−/− C57BL/6 mice infected with DENV twice, and boosted with rDIII once.
The method of generating mouse mAbs was the same, including isolation of splenocytes, hybridoma and
screening by flow cytometry with DENV-infected cells.
TS: type-specific, CrR: cross-reactive, CR: complex-reactive, GR: group-reactive.
Binding to recombinant DI/II or DIII of E protein or E protein, ND: not done.
lr: lateral ridge, str: strand, CCL: CC' loop, di: dimer interface, FL: fusion loop.
Several in-depth studies of mouse anti-E mAbs against DENV and WNV have provided critical insights into the mechanisms of neutralization including the stoichiometry (Pierson et al., 2007), maturation status (Nelson et al., 2008), temperature (Dowd et al., ), step of fusion (Thompson et al., 2009), genotype/strain difference (Austin et al., ; Sukupolvi-Petty et al., 2013), type-specific or cross-neutralization (Cockburn et al., ,; Midgley et al., 2012), structural organization, and “breathing” on virion (Lok et al., 2008; Edeling et al., ).
Epitopes recognized by human anti-E mAbs
Several technologies including EBV-immortalization of B cells, cytofusion-hybridoma, and single cell-expression cloning of plasmablasts (Wilson and Andrews, 2012) have been employed to generate human mAbs against DENV after natural infection or vaccination (Beltramello et al., ; de Alwis et al., , ; Smith et al., 2012, 2013a,b, 2014; Teoh et al., 2012; Xu et al., 2012; Costin et al., ; Tsai et al., 2013; Dejnirattisai et al., ; Priyamvada et al., 2016). Table 2 summarizes more than 300 human anti-E mAbs reported thus far. Despite different methods/antigens were used to generate and characterize these mAbs, predominant cross-reactive mAbs were identified from individuals after primary and secondary DENV infection, whereas type-specific mAbs were identified mainly from individuals after primary infection.
Table 2
| Methodsa | Immune status of hosts | # of mAbs | Specificityb TS/CrR[CR+GR] | Bindingc DI/II DIII | Epitopesd | Potent NT mAbs or remarkse | References | |
|---|---|---|---|---|---|---|---|---|
| Memory BC EBV-imm, V-cell flow, V-cell ELISA | 3 primary infections 2 secondary infections | 20 27 | 12 TS (60%) 8 CrR (40%) 1 TS (4%) 26 CrR (96%) | 8 4 1 22 | 4 4 0 4 | several TS anti-DIII and CrR anti-DI/DII | Beltramello et al., | |
| Memory BC EBV-imm, V-cell flow | 2 primary infections | 11 | 5 TS (45%) 6 CrR (55%) | ND ND | 4 2 | 303, 304, 305, 307, 310, 317, 384 | 3.7, 25.5,10.16,35.3 18.21,13.6,23.13 | de Alwis et al., |
| Memory BC EBV-imm, V-ELISA | 1 primary infection | 1 | 1 TS | ND | ND | quaternary epitope | HM14c10 | Teoh et al., 2012 |
| Memory BC hybridoma V-ELISA | 5 primary infections 5 secondary infections | 25 5 | 2 TS (8%) 23 CrR (92%) 0 TS (0%) 5 CrR (100%) | 1 19 4 | 1 4 1 | quaternary epitope | 2D22, 5J7 | Smith et al., 2012 |
| Memory BC Hybridoma, V-ELISA | 14 primary immunizations 4 primary infections | 16 24 | 0 TS (0%) 16 CrR (100%) 1 TS (4%) 23 CrR (96%) | 9 0 16 | 7 1 7 | Smith et al., 2013b | ||
| Memory BC, EBV-imm, or PCR-EC, V-ELISA | 1 secondary infection 2 primary infections | 3 | 3 CrR | 3 | 0 | 101, 109 | 1.6D | Costin et al., |
| Memory BC EBV-imm, V-cell flow, plasmablasts, SC-EC, V-ELISA | 4 primary Infections 4 secondary Infections | 28 23 | 10 TS (36%) 18 CrR (64%) 0 TS (0%) 23 CrR (100%) | ND ND ND ND | ND ND ND ND | GR mAbs: 101, 106, 107, 108, 76, 78 GR mAbs:101, 106, 107, 108, 76, 78 | GR mAbs: FL or FL+bc loop | Tsai et al., 2013 |
| Memory BC Hybridoma, V-ELISA | 6 primary infections 5 secondary infections | 9 21 | 9 CrR 21 CrR | ND ND | ND ND | 101, 106, 107, 108, 110, 111, 104 73, 78, 79 | 1M7 1C19: bc loop 1N5 | Smith et al., 2013a |
| Memory BC Hybridoma, V-ELISA | 2 primary infections 1 secondary infection | 11 23 | 3 TS (27%) 8 CrR (73%) 2 TS (9%) 21 CrR (91%) | 0 2 0 20 | 2 2 1 0 | I/II hinge | 3F9, 1L12 1M7 1F4 | Smith et al., 2014 |
| Plasmablasts SC-EC, V-ELISA | 1 primary infection 6 secondary infections | 32 113 | 2 TS (6%) 30 CrR (94%) 2 TS (2%) 111 CrR (98%) | ND ND ND ND | ND ND ND ND | EDE2 EDE1, EDE2 or FLE EDE2 EDE1, EDE2 or FLE | 50 EDE mAbs more potent NT than 46 FL mAbs | Dejnirattisai et al., |
Summary of human anti-E mAbs reported in literature.
BC, B-cells; EBV-imm, Epstein-Barr virus immortalization; V-cell flow, screen by flow cytometry using virus-infected cells; V-cell ELISA, screen by ELISA using virus-infected cells; V-ELISA, screen by ELISA using virion, PCR-EC; PCR expression cloning of Ig genes; SC-EC, Single-cell PCR expression cloning of Ig genes.
TS, type-specific; CrR, cross-reactive; CR, complex-reactive; GR, group-reactive.
Binding to recombinant DI/II or DIII of E protein, ND: not done.
Major epitopes identified are listed. EDE, E dimer epitope; FLE, fusion loop epitope (Dejnirattisai et al., ).
NT, neutralization; FL, fusion loop. Potent NT mAbs with NT50 < 0.5 μg/ml are listed.
Based on the binding to recombinant E protein, DIII or DI/II, alanine mutants, yeast library or escape mutants, group-reactive mAbs were found to recognize either residues in fusion loop or both fusion loop and bc loop, a loop next to fusion loop in DII (Costin et al., ; Smith et al., 2013a; Tsai et al., 2013), type-specific mAbs recognize epitopes in DIII, interdomain residues, DI/II hinge region or quaternary epitopes on virion (Beltramello et al., ; de Alwis et al., , ; Teoh et al., 2012; Fibriansah et al., , ,), and complex-reactive mAbs recognize DIII or E-dimer epitope which involves fusion loop and other residues (Beltramello et al., ; de Alwis et al., ; Dejnirattisai et al., ). The quaternary epitopes recognized by several type-specific potent neutralizing mAbs (14C10, 1F4, 2D22, and 5F7) are shown in Figures 3A–D (Teoh et al., 2012; Fibriansah et al., , ,); the E-dimer epitopes 1 and 2 recognized by complex-reactive potent neutralizing mAbs are shown in Figure 3E (Rouvinski et al., 2015).
Figure 3
Epitopes recognized by anti-prM mAbs
After the early reports of some mouse anti-prM mAbs (Megret et al., 1992; Roehrig et al., 1998), a large panel of human anti-prM mAs were found to be cross-reactive, weakly or non-neutralizing, and enhance DENV in FcγR cells, suggesting anti-prM response is detrimental (Dejnirattisai et al., ). Consistent with this, mouse anti-prM mAbs were reported to cause antibody-dependent enhancement (ADE) in vitro, especially for immature or partially immature DENV (Rodenhuis-Zybert et al., 2010). Since fusion loop epitopes were more exposed on immature DENV, anti-fusion loop mAbs were shown to preferentially bind immature DENV (Cherrier et al., ), enhance their infectivity in vitro (Rodenhuis-Zybert et al., 2011), and cause ADE in vivo, including monkey (Goncalvez et al., ) and lethal disease in AG129 mice (Shresta et al., 2006; Balsitis et al., ; Zellweger et al., 2010).
The epitopes of mouse anti-prM mAbs were previously reported in a conserved region of pr peptide (residues 53–67) (Huang et al., ). A recent study of 25 human anti-prM mAbs revealed several overlapping epitopes within a major antigenic site in the pr peptide; a few anti-prM mAbs can recognize E protein as well (Chan et al., ; Smith et al., 2015).
Different categories of anti-E Abs in polyclonal human serum
Previously, depletion of human sera with antigen derived from non-infecting DENV serotypes, so called heterologous serotypes, reported that the majority of anti-E Abs after primary infection was cross-reactive and a minor proportion was type-specific (Lai et al., ). This was supported by studies using WT and mutant virus-like particles (VLPs) containing mutations of cross-reactive epitopes to measure the endpoint ELISA titers and determine the proportion of cross-reactive and type-specific Abs (Crill et al., ; Lai et al., ). Another study using rDIII in depletion revealed the proportion of type-specific anti-DIII Abs was 0.4–8.1% after primary DENV infection (Wahala et al., 2009). Interestingly, an integrated analysis of 319 human anti-E mAbs from 7 studies in Table 2, of which each contained a panel of (rather than one or two) human mAbs to represent the Ab repertoire in the study subjects, revealed that the percentages of cross-reactive vs. type-specific mAbs derived from primary and secondary DENV infections were 76.8 vs. 23.2% and 97 vs. 3%, respectively (Table 3). Consistent with this, a recent study using multicolor fluorospot assay to examine memory B cell population reported that the percentages of cross-reactive vs. type-specific B-cell clones after primary and secondary infections were 52 vs. 48% and 98 vs. 0.2–2%, respectively (Hadjilaou et al., ).
Table 3
| Immune status of hosts | # of mAbs | Specificity of mAbs | Referencesb | |||
|---|---|---|---|---|---|---|
| TSa | CrRa [CR+GR] | CRa | GRa | |||
| Primary DENV infection (n = 21) | 151 | 35 (23.2%) | 116 (76.8%) | 57 (37.7%) | 59 (39.1%) | Beltramello et al., ; de Alwis et al., ; Smith et al., 2012, 2013a, 2014; Tsai et al., 2013; Dejnirattisai et al., |
| Secondary DENV infection (n = 14) | 168 | 5 (3.0%) | 163 (97.0%) | 71 (42.3%) | 92 (54.7%) | Beltramello et al., ; Smith et al., 2012, 2014; Tsai et al., 2013; Dejnirattisai et al., |
| Total (n = 35) | 319 | 40 (12.5%) | 279 (87.5%) | 128 (40.1%) | 151 (47.3%) | Beltramello et al., ; de Alwis et al., ; Smith et al., 2012, 2013a, 2014; Tsai et al., 2013; Dejnirattisai et al., |
Relationship between the specificity of human anti-E mAbs and immune status of hosts.
TS, type-specific; CrR, cross-reactive; CR, complex-reactive; GR, group-reactive. For studies that did not separate CrR mAbs into CR and GR mAbs, the CrR mAbs that bind DI/II are considered GR mAbs and those bind DIII are considered CR mAbs in this analysis.
Studies in Table 2 that characterized the binding specificity of a panel of human mAbs derived from individuals with known DENV immune status were included in the analysis.
Epitopes recognized by neutralizing anti-E Abs in polyclonal serum
It is known that following primary DENV infection, individuals develop monotypic neutralizing Abs against the infecting serotype, which correlate with the long-lived protection against that serotype (Sabin, 1952; Innis, ; Halstead, ; Imrie et al., ). After recovery from secondary infection, individuals develop multitypic neutralizing Abs not only against the previously exposed serotypes but also against the serotypes to which they have not yet been exposed (“non-exposed” serotypes) (Innis, ; Halstead, ). Such heterotypic neutralizing Abs are thought to contribute to protection against the non-exposed serotypes during the third or fourth DENV infections, as suggested by the lower rates of hospital admission (Gibbons et al., ) and reduced risk of symptomatic DENV infection in humans (Olkowski et al., 2013) as well as lower viremia in monkeys (references in Tsai et al., 2013).
Several studies have investigated the nature of anti-E Abs contributing to neutralizing activities after DENV infection. In the situation of primary infection, an initial study reported that rDIII cannot deplete the monotypic type-specific neutralizing activity after primary infection, suggesting that anti-DIII Abs do not contribute to such neutralizing activity (Wahala et al., 2009). A second study showed that DENV virions of the infecting serotype rather than those of the non-exposed serotypes or recombinant E proteins can deplete the monotypic type-specific neutralizing activity, suggesting that type-specific anti-E Abs recognizing epitopes present on virions contribute to such neutralizing activity (de Alwis et al., ). Analysis of the escape mutants of 3 potent TS human mAbs (1F4, 2D22, and 5F7) that bind to virions revealed their epitopes on the DI/II hinge region or DIII (de Alwis et al., ), which was further verified by cryo-EM studies (Fibriansah et al., , ,) (Figures 3B–D). A study of vaccinees reported reduced neutralization sensitivity to mutant (E126K/E157K) DENV1 replicon particles in 18 (77%) of 24 vaccinees receiving live-attenuated DENV1 vaccine, suggesting anti-E Abs in polyclonal serum recognizing these two residues proximal to the DI/II hinge contribute to the type-specific neutralizing activities (VanBlargan et al., 2013). This was followed by a series of studies using chimeric viruses, in which the candidate epitope residues on E protein were replaced by those of other serotypes. A study of chimeric virus containing 25 DI/II hinge residues of DENV4 in the DENV3 backbone (rDENV3/4) reported loss of neutralization in 4 primary DENV3 sera and gain of neutralization in 4 primary DENV4 sera (Messer et al., 2014), though the article was retracted due to contamination of rDENV3/4 virus stock (Messer et al., 2015). A second study using chimeric virus containing 40 DIII residues of DENV2 in the DENV4 backbone (rDENV4/2) revealed gain of neutralization in 7 primary DENV2 sera and no loss of neutralization in 4 primary DENV4 sera, suggesting these residues contribute to type-specific neutralizing activity after primary DENV2 but not DENV4 infection (Gallichotte et al., ). A recent study using chimeric virus containing 25 DI/II hinge residues of DENV3 in the DENV4 backbone (rDENV4/3) revealed >60% loss of neutralization in 3 out of 6 primary DENV4 sera and all 4 vaccinees receiving live-attenuated DENV4 vaccine, suggesting these residues contribute to type-specific neutralizing activity after primary DENV4 infection/immunization (Nivarthi et al., 2017).
Taken together, these studies suggest that type-specific Abs recognizing residues proximal to DI/II hinge, DIII complex epitope residues, and DI/II hinge residues contribute to type-specific neutralizing activity following primary DENV1 immunization, primary DENV2 infection/immunization, and primary DENV4 infection/immunization, respectively (VanBlargan et al., 2013; Gallichotte et al., ; Nivarthi et al., 2017). It is worth noting that type-specific neutralizing Abs in 23% of individuals after primary DENV1 immunization do not recognize residues proximal to DI/II hinge, suggesting the presence of other type-specific neutralizing epitope in some DENV1 vaccinees (VanBlargan et al., 2013). Similarly, 32% of type-specific neutralizing Abs after primary DENV2 infection/immunization recognize DIII residues alone, suggesting the presence of type-specific neutralizing epitopes other than DIII complex epitope in DENV2 immune serum (Gallichotte et al., ). The observation that 50% (3 out of 6) of individuals after primary DENV4 infection do not recognize the DI/II hinge residues suggests the presence of other type-specific neutralizing epitopes in DENV4 immune serum (Nivarthi et al., 2017). This is in agreement with the reports of individual variations in the specificity of anti-E Abs to different domains and their contribution to neutralizing activities in polyclonal sera after YFV vaccination and TBEV infection/immunization (Vratskikh et al., 2013; Jarmer et al., ).
In the situation of secondary DENV infection, it was reported that group-reactive anti-E mAbs derived from patients after secondary DENV infection had higher binding avidity and neutralizing potency compared with those derived after primary infection, suggesting cross-reactive anti-E Abs (including group-reactive and complex-reactive Abs) evolved from low avidity and poor neutralizing after primary infection to high avidity and potent neutralizing after secondary infection (Tsai et al., 2013). A recent study using a two-step depletion protocol to remove group-reactive and complex-reactive anti-E Abs revealed that cross-reactive anti-E Abs contributed significantly to neutralizing activities against both exposed and non-exposed DENV serotypes after secondary DENV infection/immunization (Tsai et al., 2015).
Epitopes recognized by enhancing Abs in polyclonal serum
Previous epidemiological studies have shown that individuals experiencing a secondary DENV infection had a significant higher risk of severe disease than those experiencing primary infection (Halstead, and references in). In the presence of diluted dengue immune serum, DENV replicates to produce higher titers of virus particles in human Fcγ receptor-bearing cells compared with that in the absence of serum, a phenomenon known as ADE (Halstead and O'Rourke, ; Halstead, , ). Further studies have shown that ADE is a concentration-dependent phenomenon and can be caused by both non-neutralizing mAbs and neutralizing mAbs at suboptimal concentration (Pierson et al., 2007, 2008; Nelson et al., 2008), including very potent human neutralizing mAbs (Beltramello et al., ; Teoh et al., 2012; Fibriansah et al., , ,; Dejnirattisai et al., ). Thus, induction of potent and durable neutralizing Abs has been a goal of DENV vaccine development (Murphy and Whitehead, 2011; Schwartz et al., 2015).
Using depletion protocol together with K562 cell-based ADE assay and mouse model, a recent study demonstrated that removal of cross-reactive Abs in primary DENV-immune sera ablated ADE in vitro and in vivo (de Alwis et al., ). Moreover, both recombinant E-specific Abs (including fusion loop Abs) and anti-prM Abs were shown to contribute significantly to ADE in vitro.
T-cell responses after natural DENV infection
T-cell responses after DENV infection and their role in protection or pathogenesis have been reviewed previously (Rothman, 2011; Weiskopf and Sette, 2014). Early studies of T-cell responses during acute DENV infection in patients with different disease severity suggested cross-reactive CD8 T-cells contribute to pathogenesis rather than protection (Mongkolsapaya et al., 2003; Duangchinda et al., ). However, other studies reported that the timing of T-cell response does not match with plasma leakage, a key feature of DHF/DSS (Dung et al., ). Recent studies suggested protective roles of CD8 T-cells response and the association of multifunctional CD8 T-cells with protection against disease in a Sri Lankan population (Weiskopf et al., 2013; references in Rothman, 2011). To further address the role of T-cells in protection or pathogenesis, investigating the pre-existing T-cell response and disease outcome in well-designed prospective cohorts is needed (Rothman, 2011).
Since CD8 T-cell epitopes were mapped primarily to NS proteins such as NS3 and NS5 (Mathew et al., 1996; Weiskopf et al., 2013, 2015), the moderate efficacy of CYD-TDV vaccine has been attributed to the lack of NS proteins of DENV to elicit CD8 T-cell responses (Thomas, 2015; Halstead and Russell, ). It is worth noting that structural proteins (C, prM and E) do contain CD8 T-cell epitopes (Mathew et al., 1996; Weiskopf et al., 2013, 2015) and T-cell response to DENV structural proteins has been shown in naïve individuals receiving CYD-TDV vaccine (Harenberg et al., ). Subunit candidate vaccine containing recombinant DENV E protein can induce T-cell response based on IFNγ ELISPOT assays (Manoff et al., 2015). Moreover, two successful flavivirus vaccines (JEV and TBEV vaccines) are based on inactivated virions in the absence of NS proteins (Ishikawa et al., ). Although it remains to be investigated whether NS proteins are required to be a component of dengue vaccine, evaluation of dengue vaccine in clinical trials should include the assessment of T-cell responses (Rothman et al., 2015).
Implication for vaccine strategy
Several candidate dengue vaccines are currently in different phases of clinical trials, including various formats such as live attenuated virus, purified inactivated virus, recombinant E protein, and DNA vaccine (Guzman and Harris, ; Schwartz et al., 2015). The goals are to provide long-lasting protection against each of the four serotypes, good safety profile, well-tolerated reactogenicity, suitable regimen for target population and affordable cost (Murphy and Whitehead, 2011). Following the reports of the Phase 2b and 3 trials of CYD-TDV vaccine and its subsequent licensure, several comments and reviews have been published regarding the population benefits and potential risks of this vaccine (Thomas, 2015; Halstead, ; Halstead and Russell, ; Wilder-Smith et al., 2016), implication to dengue immunopathogenesis (Screaton et al., 2015), complexity of vaccine and assays for evaluation (Flipse and Smit, ), and comparison with another promising candidate vaccine (Whitehead, 2016).
Both Abs and T-cell response contribute to protection and clearance of DENV infection. From the observations of natural DENV infection, reduction in DHF/DSS during early infancy less than 6 months, and passive Abs transfer experiments in animals, neutralizing Abs likely play a major role in protection (review by Murphy and Whitehead, 2011). However, non-neutralizing Abs and neutralizing Abs at suboptimal concentrations can cause ADE in vitro and in vivo (Goncalvez et al., ; Pierson et al., 2007, 2008; Nelson et al., 2008; Balsitis et al., ; Zellweger et al., 2010; Murphy and Whitehead, 2011). Thus, induction of durable potent neutralizing Abs and less enhancing Abs has been a goal of DENV vaccine development (Murphy and Whitehead, 2011; Schwartz et al., 2015). In this regard, the discovery of epitopes recognized by potent neutralizing mAbs following natural DENV infection have important implication for dengue vaccine development. These potent neutralizing epitopes include DIII, DI/II hinge region, quaternary epitopes on virion, E-dimer epitope, and fusion loop epitope recognized by human mAbs after secondary infection. The identification of epitopes recognized by mAbs that are weakly or non-neutralizing and enhancing, such as anti-prM mAbs, have implication for new strategy of dengue vaccine as well.
Previous reports of potent neutralizing anti-DIII mAbs in mice suggest DIII can be a potential vaccine candidate (Brien et al., ; Shrestha et al., 2010; Sukupolvi-Petty et al., 2010, 2013). While anti-DIII Abs represent only a small percentage of total anti-E Abs and do not contribute greatly to neutralizing activities in human sera (Crill et al., ; Wahala et al., 2009; Gallichotte et al., ), these observations do not preclude rDIII from being a vaccine candidate. This is because a number of potent neutralizing anti-DIII mAbs were also found in humans (Beltramello et al., ; de Alwis et al., ), suggesting such neutralizing Abs can be induced during natural DENV infection. Notably, an elegant study of WNV vaccine in mice showed that rDIII induced much lower neutralizing Abs compared with inactivated virions, whereas inactivated virions boosted with rDIII induced highest neutralizing Abs (Zlatkovic et al., 2011). How to induce high titers of neutralizing Abs by rDIII remains to be explored for the development of a subunit DENV vaccine.
The discovery of quaternary epitopes that are recognized by type-specific human potent neutralizing mAbs (14c10, 1F4, 2D22, and 5J7) suggests the importance of conformation and arrangement of E protein on virions (or VLPs) to induce potent neutralizing Abs (Teoh et al., 2012; Fibriansah et al., , ,). Notably, mAb 1F4 recognizes residues in DI/II hinge of an E monomer but cannot bind recombinant E protein, which primarily forms monomer at the concentration tested in the binding assay (Fibriansah et al., ). The difference in the angle of DI/II between virions and solution is likely to explain such discrepancy. In light of the observation that anti-prM mAbs are weakly or non-neutralizing and cause ADE (Huang et al., ; Dejnirattisai et al., ; Rodenhuis-Zybert et al., 2010, 2011), how to present E protein in the context similar to that on virions without pr or prM protein in the vaccine preparation will be challenging but promising as the next generation vaccine. This might require the approach of genetic engineering or epitope-modification to better present the immunogen and induce more potent neutralizing Abs and less enhancing Abs, thus reducing the risk of ADE. An example of epitope-modified vaccine was demonstrated by the fusion loop-mutated dengue DNA vaccine, which induced comparable neutralizing Abs but less enhancing Abs in mice compared with WT DNA vaccine (Crill et al., ; Hughes et al., ). Similarly, a recent study of fusion loop-modified ZIKV mRNA vaccine showed less enhancing Abs were induced (Richner et al., 2017).
The recent discovery of novel E-dimer epitopes recognized by human cross-reactive potent neutralizing mAbs raises the possibility that the task of inducing balanced neutralizing Abs against 4 DENV serotypes by tetravalent vaccines can be achieved by using E dimers to induce cross-reactive anti-E dimer epitope neutralizing Abs (Dejnirattisai et al., ; Rouvinski et al., 2015). However, the design of recombinant E dimers to present the right conformation of E-dimer epitope remains to be explored.
The observations that anti-fusion loop mAbs derived from secondary DENV infection have higher binding avidity and neutralizing potency compared with those derived from primary infection (Tsai et al., 2013) suggest that during secondary infection memory B cells recognizing the common epitopes expand rapidly to generate cross-reactive, high avidity, and potent neutralizing Abs through affinity maturation. This was supported by higher level and rapid increase in serum avidity, cross-reactive memory B cells and plasmablasts after secondary DENV infection compared with primary infection (Mathew et al., 2011; Wrammert et al., 2012; Xu et al., 2012; Zompi et al., 2012, references in Tsai et al., 2013). The recent report that cross-reactive anti-E Abs contributed significantly to neutralizing activities against both exposed and non-exposed DENV serotypes after secondary DENV infection not only provides an explanation for the multitypic neutralizing Abs (Tsai et al., 2015), but also suggests a strategy of sequential heterotypic immunization with two or three serotypes of live-attenuated dengue vaccine to mimic natural DENV infection and induce immunity against all four serotypes. The epidemiological observations of higher risk of DHF/DSS during secondary infection raise concerns on the possible ADE and severe disease after the second dose of sequential immunization. Notably, heterotypic immunization with monovalent live-attenuated DENV vaccine in 30 individuals revealed minimal increased viremia compared with primary immunization and no severe disease (Durbin et al., ). In addition, the recent findings that CYD-TDV vaccine on DENV-experienced individuals showed no severe diseases and higher vaccine efficacy compared with naive individuals (74.3−83.7 vs. 35.5−43.2%) oppose the safety concern of sequential heterotypic immunization (Sabchareon et al., 2012; Capeding et al., ; Hadinegoro et al., ; Villar et al., 2015).
Conclusion
The moderate efficacy, low efficacy among dengue naïve, and increased risk of hospitalization among young children during the Phase 2b and 3 trials of the first dengue vaccine (dengvaxia from Sanofi Pasteur) highlight the need for a better understanding of immunity, in particular humoral responses, after natural DENV infection. We have reviewed more than 300 human mAbs against DENV E protein and potent neutralizing epitopes reported thus far, together with human anti-prM mAbs and mouse mAbs. We have also reviewed several in-depth analyses of polyclonal human sera following DENV infection. With various sophisticated technologies of generating human mAbs, it is expected that more potent neutralizing epitopes as well as non-neutralizing or enhancing epitopes will be identified. This information together with detailed analysis of different categories of neutralizing and enhancing Abs in polyclonal sera will provide not only new insights into our understanding of dengue protection and pathogenesis, but also strategies for better immunogen design to induce more potent neutralizing Abs and less enhancing Abs for next-generation dengue vaccine development. Building upon our increasing knowledge of human mAbs against DENV, future research should continue in-depth analysis on polyclonal sera comparing those from natural infection and immunization to fine tune the correlates or surrogates of protection of Abs, and also on the memory B-cells in combination with next-generation sequencing to better understand the Abs repertoire after DENV infection and immunization.
Statements
Author contributions
WT performed experiments, analyzed data, and wrote manuscript. HL analyzed data. f96445117@ntu.edu.tw. WW designed the study, analyzed data, and wrote manuscript.
Acknowledgments
We thank Dr. Richard Kuhn and his team at the Purdue University for the permission of using cryoEM pictures in Figure 1, and Dr. Shee-Mei Lok at the Duke–NUS Graduate Medical School in Singapore for the permission of using pictures in Figure 3. This work was supported by grants R01AI110769-01 from the National Institute of Allergy and Infectious Diseases, and P20GM103516 from the National Institute of General Medical Sciences, NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AaskovJ. G.GeysenH. M.MasonT. J. (1989). Serologically defined linear epitopes in the envelope protein of dengue 2 (Jamaica strain 1409). Arch. Virol.105, 209–221.
2
AguiarM.StollenwerkN.HalsteadS. B. (2016). The impact of the newly licensed dengue vaccine in endemic countries. PLoS Negl. Trop. Dis.10:e0005179. 10.1371/journal.pntd.0005179
3
AustinS. K.DowdK. A.ShresthaB.NelsonC. A.EdelingM. A.JohnsonS.et al. (2012). Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog.8:e1002930. 10.1371/journal.ppat.1002930
4
BalsitisS. J.WilliamsK. L.LachicaR.FloresD.KyleJ. L.MehlhopE.et al. (2010). Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog.6:e1000790. 10.1371/journal.ppat.1000790
5
BeltramelloM.WilliamsK. L.SimmonsC. P.MacagnoA.SimonelliL.QuyenN. T.et al. (2010). The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe8, 271–283. 10.1016/j.chom.2010.08.007
6
BhattS.GethingP. W.BradyO. J.MessinaJ. P.FarlowA. W.MoyesC. L.et al. (2013). The global distribution and burden of dengue. Nature496, 504–507. 10.1038/nature12060
7
BrienJ. D.AustinS. K.Sukupolvi-PettyS.O'BrienK. M.JohnsonS.FremontD. H.et al. (2010). Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J. Virol.84, 10630–10643. 10.1128/JVI.01190-10
8
CalisherC. H.KarabatsosN.DalrympleJ. M.ShopeR. E.PorterfieldJ. S.WestawayE. G.et al. (1989). Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J. Gen. Virol.70, 37–43. 10.1099/0022-1317-70-1-37
9
CapedingM. R.TranN. H.HadinegoroS. R.IsmailH. I.ChotpitayasunondhT.ChuaM. N.et al. (2014). Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet384, 1358–1365. 10.1016/S0140-6736(14)61060-6
10
ChanA. H.TanH. C.ChowA. Y.LimA. P.LokS. M.MorelandN. J.et al. (2012). A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein. PLoS ONE7:e33451. 10.1371/journal.pone.0033451
11
CherrierM. V.KaufmannB.NybakkenG. E.LokS. M.WarrenJ. T.ChenB. R.et al. (2009). Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J.28, 3269–3276. 10.1038/emboj.2009.245
12
ChurdboonchartV.BhamarapravatiN.PeampramprechaS.SirinavinS. (1991). Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am. J. Trop. Med. Hyg.44, 481–493. 10.4269/ajtmh.1991.44.481
13
CockburnJ. J.Navarro SanchezM. E.FretesN.UrvoasA.StaropoliI.KikutiC. M.et al. (2012a). Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure20, 303–314. 10.1016/j.str.2012.01.001
14
CockburnJ. J.Navarro SanchezM. E.GoncalvezA. P.ZaitsevaE.SturaE. A.KikutiC. M.et al. (2012b). Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. EMBO J.31, 767–779. 10.1038/emboj.2011.439
15
CostinJ. M.ZaitsevaE.KahleK. M.NicholsonC. O.RoweD. K.GrahamA. S.et al. (2013). Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J. Virol.87, 52–66. 10.1128/JVI.02273-12
16
CrillW. D.ChangG. J. (2004). Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol.78, 13975–13986. 10.1128/JVI.78.24.13975-13986.2004
17
CrillW. D.HughesH. R.DeloreyM. J.ChangG. J. (2009). Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS ONE4:e4991. 10.1371/journal.pone.0004991
18
CrillW. D.HughesH. R.TrainorN. B.DavisB. S.WhitneyM. T.ChangG. J. (2012). Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front. Immunol.3:334. 10.3389/fimmu.2012.00334
19
da SilvaA. N.NascimentoE. J.CordeiroM. T.GilL. H.AbathF. G.MontenegroS. M.et al. (2009). Identification of continuous human B-cell epitopes in the envelope glycoprotein of dengue virus type 3 (DENV-3). PLoS ONE4:e7425. 10.1371/journal.pone.0007425
20
de AlwisR.BeltramelloM.MesserW. B.Sukupolvi-PettyS.WahalaW. M.KrausA.et al. (2011). In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl. Trop. Dis.5:e1188. 10.1371/journal.pntd.0001188
21
de AlwisR.SmithS. A.OlivarezN. P.MesserW. B.HuynhJ. P.WahalaW. M.et al. (2012). Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl. Acad. Sci. U.S.A.109, 7439–7444. 10.1073/pnas.1200566109
22
de AlwisR.WilliamsK. L.SchmidM. A.LaiC. Y.PatelB.SmithS. A.et al. (2014). Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog.10:e1004386. 10.1371/journal.ppat.1004386
23
DejnirattisaiW.JumnainsongA.OnsirisakulN.FittonP.VasanawathanaS.LimpitikulW.et al. (2010). Cross-reacting antibodies enhance dengue virus infection in humans. Science328, 745–748. 10.1126/science.1185181
24
DejnirattisaiW.WongwiwatW.SupasaS.ZhangX.DaiX.RouvinskyA.et al. (2015). A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol.16, 170–177. 10.1038/ni.3058
25
DowdK. A.JostC. A.DurbinA. P.WhiteheadS. S.PiersonT. C. (2011). A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog.7:e1002111. 10.1371/journal.ppat.1002111
26
DuangchindaT.DejnirattisaiW.VasanawathanaS.LimpitikulW.TangthawornchaikulN.MalasitP.et al. (2010). Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc. Natl. Acad. Sci. U.S.A.107, 16922–16927. 10.1073/pnas.1010867107
27
DungN. T.DuyenH. T.ThuyN. T.NgocT. V.ChauN. V.HienT. T.et al. (2010). Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue. J. Immunol.184, 7281–7287. 10.4049/jimmunol.0903262
28
DurbinA. P.SchmidtA.ElwoodD.WanionekK. A.LovchikJ.ThumarB.et al. (2011). Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic. J. Infect. Dis.203, 327–334. 10.1093/infdis/jiq059
29
EdelingM. A.AustinS. K.ShresthaB.DowdK. A.MukherjeeS.NelsonC. A.et al. (2014). Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement. PLoS Pathog.10:e1004072. 10.1371/journal.ppat.1004072
30
FibriansahG.IbarraK. D.NgT. S.SmithS. A.TanJ. L.LimX. N.et al. (2015a). Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science349, 88–91. 10.1126/science.aaa8651
31
FibriansahG.TanJ. L.SmithS. A.de AlwisA. R.NgT. S.KostyuchenkoV. A.et al. (2014). A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol. Med.6, 358–371. 10.1002/emmm.201303404
32
FibriansahG.TanJ. L.SmithS. A.de AlwisR.NgT. S.KostyuchenkoV. A.et al. (2015b). A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat. Commun.6:6341. 10.1038/ncomms7341
33
FlascheS.JitM.Rodríguez-BarraquerI.CoudevilleL.ReckerM.KoelleK.et al. (2016). The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (dengvaxia): a model comparison study. PLoS Med.13:e1002181. 10.1371/journal.pmed.1002181
34
FlipseJ.SmitJ. M. (2015). The complexity of a dengue vaccine: a review of the human antibody response. PLoS Negl. Trop. Dis.9:e0003749. 10.1371/journal.pntd.0003749
35
GallichotteE. N.WidmanD. G.YountB. L.WahalaW. M.DurbinA.WhiteheadS.et al. (2015). A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. MBio6, e01461–e01415. 10.1128/mBio.01461-15
36
GibbonsR. V.KalanaroojS.JarmanR. G.NisalakA.VaughnD. W.EndyT. P.et al. (2007). Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am. J. Trop. Med. Hyg.77, 910–913.
37
GoncalvezA. P.EngleR. E.St ClaireM.PurcellR. H.LaiC. J. (2007). Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl. Acad. Sci. U.S.A.104, 9422–9427. 10.1073/pnas.0703498104
38
GromowskiG. D.BarrettA. D. (2007). Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology366, 349–360. 10.1016/j.virol.2007.05.042
39
GromowskiG. D.BarrettN. D.BarrettA. D. (2008). Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol.82, 8828–8837. 10.1128/JVI.00606-08
40
GuyB.BriandO.LangJ.SavilleM.JacksonN. (2015). Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward. Vaccine33, 7100–7111. 10.1016/j.vaccine.2015.09.108
41
GuzmanM. G.HarrisE. (2015). Dengue. Lancet385, 453–465. 10.1016/S0140-6736(14)60572-9
42
HadinegoroS. R.Arredondo-GarcíaJ. L.CapedingM. R.DesedaC.ChotpitayasunondhT.DietzeR.et al. (2015). Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med.373, 1195–1206. 10.1056/NEJMoa1506223
43
HadjilaouA.GreenA. M.ColomaJ.HarrisE. (2015). Single-cell analysis of B cell/antibody cross-reactivity using a novel multicolor fluorospot assay. J. Immunol.195, 3490–3496. 10.4049/jimmunol.1500918
44
HalsteadS. B. (1988). Pathogenesis of dengue: challenges to molecular biology. Science239, 476–481. 10.1126/science.3277268
45
HalsteadS. B. (2003). Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res.60, 421–467. 10.1016/S0065-3527(03)60011-4
46
HalsteadS. B. (2016). Critique of World Health Organization recommendation of a dengue vaccine. J. Infect. Dis.214, 1793–1795. 10.1093/infdis/jiw340
47
HalsteadS. B.O'RourkeE. J. (1977). Antibody-enhanced dengue virus infection in primate leukocytes. Nature265, 739–741. 10.1038/265739a0
48
HalsteadS. B.RussellP. K. (2016). Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine34, 1643–1647. 10.1016/j.vaccine.2016.02.004
49
HarenbergA.BegueS.MamessierA.Gimenez-FourageS.Ching SeahC.Wei LiangA.et al. (2013). Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum. Vaccin. Immunother.9, 2317–2325. 10.4161/hv.25562
50
HuangK. J.YangY. C.LinY. S.HuangJ. H.LiuH. S.YehT. M.et al. (2006). The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J. Immunol.176, 2825–2832. 10.4049/jimmunol.176.5.2825
51
HughesH. R.CrillW. D.ChangG. J. (2012). Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol. J.9:115. 10.1186/1743-422X-9-115
52
ImrieA.MeeksJ.GuraryA.SukhbaatarM.TruongT. T.CroppC. B.et al. (2007). Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol.20, 672–675. 10.1089/vim.2007.0050
53
InnisB. L. (1997). Antibody responses to dengue virus infection, in Dengue and Dengue Hemorrhagic Fever, eds GublerD. J.KunoG. (Cambridge, MA: CAB International), 221–244.
54
IshikawaT.YamanakaA.KonishiE. (2014). A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine32, 1326–1337. 10.1016/j.vaccine.2014.01.040
55
JarmerJ.ZlatkovicJ.TsouchnikasG.VratskikhO.Strau,ßJ.AberleJ. H.et al. (2014). Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination. J. Virol.88, 13845–13857. 10.1128/JVI.02086-14
56
JunjhonJ.EdwardsT. J.UtaipatU.BowmanV. D.HoldawayH. A.ZhangW.et al. (2010). Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J. Virol.84, 8353–8358. 10.1128/JVI.00696-10
57
KielianM.ReyF. A. (2006). Virus membrane-fusion proteins: more than one way to make a hairpin. Nat. Rev. Microbiol.4, 67–76. 10.1038/nrmicro1326
58
KuhnR. J.ZhangW.RossmannM. G.PletnevS. V.CorverJ.LenchesE.et al. (2002). Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell108, 717–725. 10.1016/S0092-8674(02)00660-8
59
LaiC. Y.TsaiW. Y.LinS. R.KaoC. L.HuS. P.KingC. C.et al. (2008). Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J. Virol.82, 6631–6643. 10.1128/JVI.00316-08
60
LaiC. Y.WilliamsK. L.WuY. C.KnightS.BalmasedaA.HarrisE.et al. (2013). Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl. Trop. Dis.7:e245110.1371/journal.pntd.0002451
61
LiL.LokS. M.YuI. M.ZhangY.KuhnR. J.ChenJ.et al. (2008). The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science319, 1830–1834. 10.1126/science.1153263
62
LinH. E.TsaiW. Y.LiuI. J.LiP. C.LiaoM. Y.TsaiJ. J.et al. (2012). Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high-throughput assay. PLoS Negl. Trop. Dis.6:e1447. 10.1371/journal.pntd.0001447
63
LokS. M.KostyuchenkoV.NybakkenG. E.HoldawayH. A.BattistiA. J.Sukupolvi-PettyS.et al. (2008). Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol.15, 312–317. 10.1038/nsmb.1382
64
ManoffS. B.GeorgeS. L.BettA. J.YelmeneM. L.DhanasekaranG.EggemeyerL.et al. (2015). Preclinical and clinical development of a dengue recombinant subunit vaccine. Vaccine33, 7126–7134. 10.1016/j.vaccine.2015.09.101
65
MathewA.KuraneI.RothmanA. L.ZengL. L.BrintonM. A.EnnisF. A. (1996). Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J. Clin. Invest.98, 1684–1691.
66
MathewA.WestK.KalayanaroojS.GibbonsR. V.SrikiatkhachornA.GreenS.et al. (2011). B-cell responses during primary and secondary dengue virus infections in humans. J. Infect. Dis.204, 1514–1522. 10.1093/infdis/jir607
67
MegretF.HugnotJ. P.FalconarA.GentryM. K.MorensD. M.MurrayJ. M.et al. (1992). Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology187, 480–491.
68
MesserW. B.de AlwisR.YountB. L.RoyalS. R.HuynhJ. P.SmithS. A.et al. (2014). Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc. Natl. Acad. Sci. U.S.A.111, 1939–1944. 10.1073/pnas.1317350111
69
MesserW. B.de AlwisR.YountB. L.RoyalS. R.HuynhJ. P.SmithS. A.et al. (2015). Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc. Natl. Acad. Sci. U.S.A.112, E2738. 10.1073/pnas.1506982112
70
MidgleyC. M.FlanaganA.TranH. B.DejnirattisaiW.ChawansuntatiK.JumnainsongA.et al. (2012). Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. J. Immunol.188, 4971–4979. 10.4049/jimmunol.1200227
71
ModisY.OgataS.ClementsD.HarrisonS. C. (2004). Structure of the dengue virus envelope protein after membrane fusion. Nature427, 313–319. 10.1038/nature02165
72
MongkolsapayaJ.DejnirattisaiW.XuX. N.VasanawathanaS.TangthawornchaikulN.ChairunsriA.et al. (2003). Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med.9, 921–927. 10.1038/nm887
73
MukhopadhyayS.KuhnR. J.RossmannM. G. (2005). A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol.3, 13–22. 10.1038/nrmicro1067
74
MurphyB. R.WhiteheadS. S. (2011). Immune response to dengue virus and prospects for a vaccine. Annu. Rev. Immunol.29, 587–619. 10.1146/annurev-immunol-031210-101315
75
NelsonS.JostC. A.XuQ.EssJ.MartinJ. E.OliphantT.et al. (2008). Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog.4:e1000060. 10.1371/journal.ppat.1000060
76
NivarthiU. K.KoseN.SapparapuG.WidmanD.GallichotteE.PfaffJ. M.et al. (2017). Mapping the human memory B cell and serum neutralizing antibody responses to dengue virus serotype 4 infection and vaccination. J Virol. 91:e02041-16. 10.1128/JVI.02041-16
77
OlkowskiS.ForsheyB. M.MorrisonA. C.RochaC.VilcarromeroS.HalseyE. S.et al. (2013). Reduced risk of disease during postsecondary dengue virus infections. J. Infect. Dis.208, 1026–1033. 10.1093/infdis/jit273
78
PereraR.KuhnR. J. (2008). Structural proteomics of dengue virus. Curr. Opin. Microbiol.11, 369–377. 10.1016/j.mib.2008.06.004
79
PereraR.KhaliqM.KuhnR. J. (2008). Closing the door on flaviviruses: entry as a target for antiviral drug design. Antiviral Res.80, 11–22. 10.1016/j.antiviral.2008.05.004
80
PiersonT. C.DiamondM. S. (2013). Flaviviruses, in Fields Virology, 6th Edn, eds KnipeD. M.HowleyP. M. (Philadelphia, PA: Lippincott William & Wilkins), 747–794.
81
PiersonT. C.FremontD. H.KuhnR. J.DiamondM. S. (2008). Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe4, 229–238. 10.1016/j.chom.2008.08.004
82
PiersonT. C.XuQ.NelsonS.OliphantT.NybakkenG. E.FremontD. H.et al. (2007). The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe1, 135–145. 10.1016/j.chom.2007.03.002
83
PriyamvadaL.ChoA.OnlamoonN.ZhengN. Y.HuangM.KovalenkovY.et al. (2016). B cell responses during secondary dengue virus infection are dominated by highly cross-reactive, memory-derived plasmablasts. J. Virol.90, 5574–5585. 10.1128/JVI.03203-15
84
RichnerJ. M.HimansuS.DowdK. A.ButlerS. L.SalazarV.FoxJ. M.et al. (2017). Modified mRNA vaccines protect against zika virus infection. Cell168, 1114.e10–1125.e10. 10.1016/j.cell.2017.02.017
85
Rodenhuis-ZybertI. A.MoeskerB.da Silva VoorhamJ. M.van der Ende-MetselaarH.DiamondM. S.WilschutJ.et al. (2011). A fusion-loop antibody enhances the infectious properties of immature flavivirus particles. J. Virol.85, 11800–11808. 10.1128/JVI.05237-11
86
Rodenhuis-ZybertI. A.van der SchaarH. M.da Silva VoorhamJ. M.van der Ende-MetselaarH.LeiH. Y.WilschutJ.et al. (2010). Immature dengue virus: a veiled pathogen?PLoS Pathog.6:e1000718. 10.1371/journal.ppat.1000718
87
RoehrigJ. T.BolinR. A.KellyR. G. (1998). Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology246, 317–328.
88
RoehrigJ. T.VolpeK. E.SquiresJ.HuntA. R.DavisB. S.ChangG. J. J. (2004). Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein. J. Virol.78, 2648–2652. 10.1128/JVI.78.5.2648-2652.2004
89
RothmanA. L. (2011). Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat. Rev. Immunol.11, 532–543. 10.1038/nri3014
90
RothmanA. L.CurrierJ. R.FribergH. L.MathewA. (2015). Analysis of cell-mediated immune responses in support of dengue vaccine development efforts. Vaccine33, 7083–7090. 10.1016/j.vaccine.2015.09.104
91
RouvinskiA.Guardado-CalvoP.Barba-SpaethG.DuquerroyS.VaneyM. C.KikutiC. M.et al. (2015). Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature520, 109–113. 10.1038/nature14130
92
SabchareonA.WallaceD.SirivichayakulC.LimkittikulK.ChanthavanichP.SuvannadabbaS.et al. (2012). Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet380, 1559–1567. 10.1016/S0140-6736(12)61428-7
93
SabinA. B. (1952). Research on dengue during World War II. Am. J. Trop. Med. Hyg.1, 30–50.
94
SchwartzL. M.HalloranM. E.DurbinA. P.LonginiI. M.Jr. (2015). The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine33, 3293–3298. 10.1016/j.vaccine.2015.05.010
95
ScreatonG.MongkolsapayaJ.YacoubS.RobertsC. (2015). New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol.12, 745–759. 10.1038/nri3916
96
Se-ThoeS. Y.NgM. M.LingA. E. (1999). Retrospective study of Western blot profiles in immune sera of natural dengue virus infections. J. Med. Virol.57, 322–330.
97
ShrestaS.ShararK. L.PrigozhinD. M.BeattyP. R.HarrisE. (2006). Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol.80, 10208–10217. 10.1128/JVI.00062-06
98
ShresthaB.BrienJ. D.Sukupolvi-PettyS.AustinK.EdelingM. A.KimT.et al. (2010). The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog.6:e1000823. 10.1371/journal.ppat.1000823
99
SmithS. A.de AlwisA. R.KoseN.HarrisE.IbarraK. D.KahleK. M.et al. (2013a). The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio4, e00873–e00813. 10.1128/mBio.00873-13
100
SmithS. A.de AlwisA. R.KoseN.JadiR. S.de SilvaA. M.CroweJ. E.Jr. (2014). Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J. Virol.88, 12233–12241. 10.1128/JVI.00247-14
101
SmithS. A.de AlwisR.KoseN.DurbinA. P.WhiteheadS. S.de SilvaA. M.et al. (2013b). Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J. Infect. Dis.207, 1898–1908. 10.1093/infdis/jit119
102
SmithS. A.NivarthiU. K.de AlwisR.KoseN.SapparapuG.BombardiR.et al. (2015). Dengue virus prM-specific human monoclonal antibodies with virus replication enhancing properties recognize a single immunodominant antigenic site. J. Virol.90, 780–789. 10.1128/JVI.01805-15
103
SmithS. A.ZhouY.OlivarezN. P.BroadwaterA. H.de SilvaA. M.CroweJ. E.Jr. (2012). Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J. Virol.86, 2665–2675. 10.1128/JVI.06335-11
104
StiasnyK.KiermayrS.HolzmannH.HeinzF. X. (2006). Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol.80, 9557–9568. 10.1128/JVI.00080-06
105
Sukupolvi-PettyS.AustinK.PurthaW. E.OliphantT.NybakkenG. E.SchlesingerJ. J.et al. (2007). Type and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol.81, 12816–12826. 10.1128/JVI.00432-07
106
Sukupolvi-PettyS.AustinS. K.EngleM.BrienJ. D.DowdK. A.WilliamsK. L.et al. (2010). Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J. Virol.84, 9227–9239. 10.1128/JVI.01087-10
107
Sukupolvi-PettyS.BrienJ. D.AustinS. K.ShresthaB.SwayneS.KahleK.et al. (2013). Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J. Virol.87, 8826–8842. 10.1128/JVI.01314-13
108
TeohE. P.KukkaroP. P.TeoE. W.LimA. P.TanT. T.YipA.et al. (2012). The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci. Transl. Med.4, 139ra83. 10.1126/scitranslmed.3003888
109
ThomasS. J. (2015). Preventing dengue - is the possibility now a reality?N. Engl. J. Med.372, 172–173. 10.1056/NEJMe1413146
110
ThompsonB. S.MoeskerB.SmitJ. M.WilschutJ.DiamondM. S.FremontD. H. (2009). A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog.5:e1000453. 10.1371/journal.ppat.1000453
111
TsaiW. Y.DurbinA.TsaiJ. J.WhiteheadS.WangW. K. (2015). Complexity of neutralization antibodies against multiple dengue viral serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies. J. Virol.89, 7348–7362. 10.1128/JVI.00273-15
112
TsaiW. Y.LaiC. Y.WuY. C.LinH. E.EdwardsE.JumnainsongA.et al. (2013). High avidity and potent neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. J. Virol.87, 12562–12575. 10.1128/JVI.00871-13
113
ValdesK.AlvarezM.PupoM.VazquezS.RodriguezR.GuzmanM. G. (2000). Human Dengue antibodies against structural and nonstructural proteins. Clin. Diagn. Lab. Immunol.7, 856–857. 10.1128/cdli.7.5.856-857.2000
114
VanBlarganL. A.MukherjeeS.DowdK. A.DurbinA. P.WhiteheadS. S.PiersonT. C. (2013). The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog.9:e1003761. 10.1371/journal.ppat.1003761
115
VaughnD. W.NisalakA.SolomonT.KalayanaroojS.DungN. M.KneenR.et al. (1999). Rapid serologic diagnosis of dengue virus infection using a commercial capture ELISA that distinguishes primary and secondary infections. Am. J. Trop. Med. Hyg.60, 693–698.
116
VillarL.DayanG. H.Arredondo-GarcíaJ. L.RiveraD. M.CunhaR.DesedaC.et al. (2015). Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America. N. Engl. J. Med.372, 113–123. 10.1056/NEJMoa1411037
117
VratskikhO.StiasnyK.ZlatkovicJ.TsouchnikasG.JarmerJ.KarrerU.et al. (2013). Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog.9:e1003458. 10.1371/journal.ppat.1003458
118
WahalaW. M.KrausA. A.HaymoreL. B.Accavitti-LoperM. A.de SilvaA. M. (2009). Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology392, 103–113. 10.1016/j.virol.2009.06.037
119
WeiskopfD.SetteA. (2014). T-cell immunity to infection with dengue virus in humans. Front. Immunol.5:93. 10.3389/fimmu.2014.00093
120
WeiskopfD.AngeloM. A.BangsD. J.SidneyJ.PaulS.PetersB.et al. (2015). The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J. Virol.89. 120–128. 10.1128/jvi.02129-14
121
WeiskopfD.AngeloM. A.de AzeredoE. L.SidneyJ.GreenbaumJ. A.FernandoA. N.et al. (2013). Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc. Natl. Acad. Sci. U.S.A.110, E2046–E2053. 10.1073/pnas.1305227110
122
WhiteheadS. S. (2016). Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?Expert Rev. Vaccines15, 509–517. 10.1586/14760584.2016.1115727
123
Wilder-SmithA.VanniceK. S.HombachJ.FarrarJ.NolanT. (2016). Population Perspectives and World Health Organization Recommendations for CYD-TDV Dengue Vaccine. J. Infect. Dis.214, 1796–1799. 10.1093/infdis/jiw341
124
WilsonP. C.AndrewsS. F. (2012). Tools to therapeutically harness the human antibody response. Nat. Rev. Immunol.12, 709–719. 10.1038/nri3285
125
World Health Organization (2009). Dengue Hemorrhagic Fever: Diagnosis, Treatment, Prevention and Control, 3rd Edn, Geneva.
126
WrammertJ.OnlamoonN.AkondyR. S.PerngG. C.PolsrilaK.ChandeleA.et al. (2012). Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J. Virol.86, 2911–2918. 10.1128/JVI.06075-11
127
XuM.HadinotoV.AppannaR.JoenssonK.TohY. X.BalakrishnanT.et al. (2012). Plasmablasts generated during repeated dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes. J. Immunol.189, 5877–5885. 10.4049/jimmunol.1201688
128
YuI. M.ZhangW.HoldawayH. A.LiL.KostyuchenkoV. A.ChipmanP. R.et al. (2008). Structure of the immature dengue virus at low pH primes proteolytic maturation. Science319, 1834–1837. 10.1126/science.1153264
129
ZellwegerR. M.PrestwoodT. R.ShrestaS. (2010). Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe7, 128–139. 10.1016/j.chom.2010.01.004
130
ZhangW.ChipmanP. R.CorverJ.JohnsonP. R.ZhangY.MukhopadhyayS.et al. (2003). Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat. Struct. Biol.10, 907–912. 10.1038/nsb990
131
ZhangX.GeP.YuX.BrannanJ. M.BiG.ZhangQ.et al. (2013). Cryo-EM structure of the mature dengue virus at 3.5-Å resolution. Nat. Struct. Mol. Biol.20, 105–110. 10.1038/nsmb.2463
132
ZhangY.CorverJ.ChipmanP. R.ZhangW.PletnevS. V.SedlakD.et al. (2003). Structures of immature flavivirus particles. EMBO J.22, 2604–2613. 10.1093/emboj/cdg270
133
ZlatkovicJ.StiasnyK.HeinzF. X. (2011). Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice. J. Virol.85, 1994–2003. 10.1128/JVI.01886-10
134
ZompiS.MontoyaM.PohlO.BalmasedaA.HarrisE. (2012). Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl. Trop. Dis.6:e1568. 10.1371/journal.pntd.0001568
Summary
Keywords
dengue virus, antibody, envelope protein, precursor membrane protein, epitopes
Citation
Tsai W-Y, Lin H-E and Wang W-K (2017) Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development. Front. Microbiol. 8:1372. doi: 10.3389/fmicb.2017.01372
Received
14 March 2017
Accepted
06 July 2017
Published
20 July 2017
Volume
8 - 2017
Edited by
José A. Melero, Instituto de Salud Carlos III, Spain
Reviewed by
Youichi Suzuki, Osaka Medical College, Japan; Takayuki Hishiki, Tokyo Metropolitan Institute of Medical Science, Japan
Updates
Copyright
© 2017 Tsai, Lin and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wei-Kung Wang wangwk@hawaii.edu
This article was submitted to Virology, a section of the journal Frontiers in Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.